1255339-42-4

Basic information

• Product Name: 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one
• Synonyms: 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one
• CAS NO: 1255339-42-4
• Molecular Weight: 503.527
• Mol File: 1255339-42-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one(1255339-42-4)
• EPA Substance Registry System: 4-methyl-1-(2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]-pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-2-one(1255339-42-4)

Safety Data

• Hazardous Substances Data: 1255339-42-4(Hazardous Substances Data)

Upstream product

• 1240300-06-4 2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)-phenoxy)ethanol 
• 34770-60-0 4-methyl-2-oxo-piperazine 
• 1240300-07-5 2-(4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)-phenoxy)ethylmethanesulfonate 
• 1869912-48-0 4-(piperidine-4-yl)phenol hydrobromide 
• 40971-95-7 6-chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine 
• 1166820-04-7 4-(1-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenol 
• 50-00-0 formaldehyd 
• 1255341-08-2 1-[2-(4-{1-[3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl}phenoxy)ethyl]piperazin-2-one 

Relevant articles and documents

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)

Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical